These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36579630)

  • 1. The current clinical approach to difficult-to-treat basal cell carcinomas.
    Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
    Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cemiplimab for locally advanced and metastatic basal cell carcinoma.
    Damsin T; Lebas E; Marchal N; Rorive A; Nikkels AF
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):243-248. PubMed ID: 35175882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023.
    Peris K; Fargnoli MC; Kaufmann R; Arenberger P; Bastholt L; Seguin NB; Bataille V; Brochez L; Del Marmol V; Dummer R; Forsea AM; Gaudy-Marqueste C; Harwood CA; Hauschild A; Höller C; Kandolf L; Kellerners-Smeets NWJ; Lallas A; Leiter U; Malvehy J; Marinović B; Mijuskovic Z; Moreno-Ramirez D; Nagore E; Nathan P; Stratigos AJ; Stockfleth E; Tagliaferri L; Trakatelli M; Vieira R; Zalaudek I; Garbe C;
    Eur J Cancer; 2023 Oct; 192():113254. PubMed ID: 37604067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
    Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
    Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
    Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
    Peris K; Fargnoli MC; Garbe C; Kaufmann R; Bastholt L; Seguin NB; Bataille V; Marmol VD; Dummer R; Harwood CA; Hauschild A; Höller C; Haedersdal M; Malvehy J; Middleton MR; Morton CA; Nagore E; Stratigos AJ; Szeimies RM; Tagliaferri L; Trakatelli M; Zalaudek I; Eggermont A; Grob JJ;
    Eur J Cancer; 2019 Sep; 118():10-34. PubMed ID: 31288208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
    Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
    Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
    Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
    Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
    Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
    Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
    Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Perspectives in the Treatment of Locally Advanced Basal Cell Carcinoma.
    Gupta N; Ruiz ES
    Drug Des Devel Ther; 2022; 16():183-190. PubMed ID: 35058688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Swiss Recommendations for Cutaneous Basal Cell Carcinoma.
    Ramelyte E; Nägeli MC; Hunger R; Merat R; Gaide O; Navarini AA; Cozzio A; Wagner NB; Maul LV; Dummer R
    Dermatology; 2023; 239(1):122-131. PubMed ID: 36137524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
    Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
    BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced basal cell carcinoma: What dermatologists need to know about treatment.
    Wilson M; Johnson RP; Senft SC; Pan EY; Krakowski AC
    J Am Acad Dermatol; 2022 Jun; 86(6S):S14-S24. PubMed ID: 35577406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the drug management of basal cell carcinoma.
    Ramelyte E; Restivo G; Mannino M; Levesque MP; Dummer R
    Expert Opin Pharmacother; 2022 Apr; 23(5):573-582. PubMed ID: 35081851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
    Véron M; Chevret S; Grob JJ; Beylot-Barry M; Saiag P; Fléchon A; You B; Maubec E; Jouary T; Toulemonde E; Jamme P; Gambotti L; Lamrani-Ghaouti A; Dupuy A; Lebbe C; Seguin NB; Houede N; Leccia MT; Le Du F; de Pontville M; Gaudy-Marquestre C; Guillot B; Simon C; Marabelle A; Mortier L
    Eur J Cancer; 2022 Dec; 177():103-111. PubMed ID: 36335780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
    Doan HQ; Chen L; Nawas Z; Lee HH; Silapunt S; Migden M
    Oncotarget; 2021 Sep; 12(20):2089-2100. PubMed ID: 34611482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
    Mesti T; Sever M; Ocvirk J
    Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.